This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Mulatero P et al. (2004) Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 89: 1045–1050
Pratt-Ubunama MN et al. (2005) Aldosterone antagonism: an emerging strategy for effective blood pressure lowering. Curr Hypertens Rep 7: 186–192
Giacchetti G et al. (2006) Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 24: 737–745
Milliez P et al. (2005) Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45: 1243–1248
Nussberger J et al. (2002) Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 39: E1–E8
Acknowledgements
The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Krakoff, L. Are elevated aldosterone levels associated with refractory hypertension?. Nat Rev Endocrinol 2, 604–605 (2006). https://doi.org/10.1038/ncpendmet0314
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0314